Evidence map›Paper›PMID 32588458›Full record

ArticleThe Journal of pharmacy and pharmacology2020

A CGRP receptor antagonist peptide formulated for nasal administration to treat migraine.

Bengt von Mentzer, Andrew F Russo, Zhongming Zhang, Adisa Kuburas, Patrick M Killoran, Vera D'Aloisio, Laura Nizic, Vicky Capel, David A Kendall, Christopher R Coxon and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacy and pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 5 countries.

Bengt von MentzerInnovipharm Limited, West Kirby, UK.
Andrew F RussoDepartment of Molecular Physiology and Biophysics, Center for Prevention and Treatment of Visual Loss, Veterans Administration Health Center, University of Iowa, Iowa City, IA, USA.ORCID https://orcid.org/0000-0002-8156-5649
Zhongming ZhangCollege of Medicine, Henan Key Laboratory of Zhang Zhongjing Formulae and Herbs for Immunoregulation, Nanyang Institute of Technology, Nanyang, Henan, China.
Adisa KuburasDepartment of Molecular Physiology and Biophysics, Center for Prevention and Treatment of Visual Loss, Veterans Administration Health Center, University of Iowa, Iowa City, IA, USA.
Patrick M KilloranDivision of Structural Biology (STRUBI), Harwell Campus, University of Oxford, Didcot, UK.ORCID https://orcid.org/0000-0001-7294-405X
Vera D'AloisioSchool of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK.
Laura NizicFaculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia.
Vicky CapelCatalent Pharma Solutions, Nottingham, UK.
David A KendallInnovipharm Limited, West Kirby, UK.
Christopher R CoxonInstitute of Chemical Sciences, School of Engineering and Physical Sciences, Heriot-Watt University, Edinburgh, UK.ORCID https://orcid.org/0000-0002-3375-3901
Gillian A HutcheonSchool of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK.ORCID https://orcid.org/0000-0002-9786-2074
Innovate UK · GBLiverpool John Moores University · GBUniversity of Iowa · USCatalent (United Kingdom) · GBHeriot-Watt University · GBNanyang Institute of Technology · CNUniversity of Oxford · GBUniversity of Zagreb · HR

Funding

Perivascular mechanisms of CGRP-induced migraine symptomsR01NS075599 · NINDS · UNIVERSITY OF IOWA · PI RUSSO, ANDREW F · 2011 to 2023
$5.0M
Foundation for the National Institutes of Health NS075599Innovate UK (Biomedical Catalyst Project) 132677NINDS NIH HHS R01 NS075599
6 · The paper itself

Abstract

objectivesTo investigate the formulation of the peptide-based antagonist (

methodsPeptide sequences were prepared using automated methods and purified by preparative HPLC. Their structure and stability were determined by LC-MS. Antagonist potency was assessed by measuring CGRP-stimulated cAMP accumulation in SK-N-MC, cells and in CHO cells overexpressing the human CGRP receptor. In vivo activity was tested in plasma protein extravasation (PPE) studies using Evans blue dye accumulation. Peptide-containing chitosan microparticles were prepared by spray drying. KEY

findings(

conclusions(

Indexed as

Administration, IntranasalAnimalsCalcitonin Gene-Related Peptide Receptor AntagonistsCell Line, TumorCHO CellsCricetinaeCricetulusDose-Response Relationship, DrugDrug CompoundingMiceMice, Inbred C57BLMigraine DisordersReceptors, Calcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistsReceptors, Calcitonin Gene-Related PeptideaCGRP (27-37)aCGRP (8-37)cAMPplasma extravasationSK-N-MC

Identifiers

PMID32588458
PMCPMC7486274
OpenAlexW3038032073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.